Business

Mar 13, 2026: Novo Nordisk vs. Hims & Hers: The GLP-1 Feud That Could Define a $200 Billion Market

Apr 3, 202600:32:51Business

The feud between Novo Nordisk (NYSE:NVO) and Hims & Hers (NYSE:HIMS) has been one of the most dramatic storylines in biotech investing — and it just took a major new turn. Simon Erickson breaks down the four-year saga: f...

About This Episode

Mar 13, 2026: Novo Nordisk vs. Hims & Hers: The GLP-1 Feud That Could Define a $200 Billion Market is an episode from The 7investing Podcast by 7investing. The feud between Novo Nordisk (NYSE:NVO) and Hims & Hers (NYSE:HIMS) has been one of...

Podcast

This episode belongs to The 7investing Podcast.

Listen Online

Use the player on this page to stream the episode online.

Episode Details

Published Apr 3, 2026, 00:32:51 long, audio available.

Mar 13, 2026: Novo Nordisk vs. Hims & Hers: The GLP-1 Feud That Could Define a $200 Billion Market

About This Episode

Related Episodes